Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in o...
Adverum is a clinical-stage gene therapy compan...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
LoveBug Probiotics brings customers an award-winning range of probiotic supplement...
LoveBug Probiotics brings customers an award-wi...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.